Story · Medicine & Biotech
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
6 outlets · first reported by 日経メディカル on · latest · 55 hours of coverage · 3 countries
The Food and Drug Administration rejected a treatment for a type of lung cancer developed by the U.S.-based biotech Summit Therapeutics and the Chinese drugmaker Akeso, Summit said on Sunday. In a letter sent to the companies, FDA regulators said the drug, called ivonescimab, could not be approved… (STAT News)
Coverage, in order
-
FDA declines to approve ivonescimab plus chemotherapy for EGFR-mutant NSCLC progressing after third-generation EGFR-TKI第3世代EGFR-TKI治療で増悪したEGFR変異陽性NSCLCに対するivonescimabと化学療法の併用療法をFDAは承認せず
Summit Therapeutics announced the decision on 15 November.米Summit Therapeutics社は11月15日、第3世代EGFR-TKI治療で増悪したEGFR変異陽性進行非小細胞肺癌(NSCLC)に対する、抗PD-1/VEGF二重特異性抗体ivonescimab(SMT112、AK112)と化学療法(白金系抗癌薬ベースの2剤併用)の併用療法の申請について、米食品医薬品局(FDA)がCRL(Complete Response Letter)を発出したと発表した。FDAは、主要評価項目の1つである無増悪生存期間(PFS)は有意に改善したものの、全生存期間(OS)で統計学的有意差が確認されていないとして、現時点では承認しなかった。
-
STAT+: FDA rejects lung cancer treatment ivonescimab from Summit TherapeuticsThe Food and Drug Administration rejected a treatment for a type of lung cancer developed by the U.S.-based biotech Summit Therapeutics and the Chinese drugmaker Akeso, Summit said on Sunday. In a letter sent to the companies, FDA regulators said the drug, called ivonescimab, could not be approved…
-
FDA won't approve Summit, Akeso's ivonescimab
FDA won't approve Summit, Akeso's ivonescimab Phil.Taylor Sun, 15/11/2026 - 18:23
-
Tom Powles: Ivonescimab Plus Chemotherapy Faces FDA Rejection in TKI-Refractory Lung CancerTom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared on X: “Ivonescimab (with chemo) has been rejected by FDA in EGFRm TKI refractory lung cancer. The trial
-
Jon Wigginton: FDA Complete Response Letter for Ivonescimab in Post-TKI NSCLCJon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn: “Ivonescimab BLA seeking approval in patients with locally-advanced or metastatic NSCLC post TKI rejected by FDA
-
Masahiro Torasawa: FDA Declines to Approve Ivonescimab Plus Chemotherapy For EGFR Mutated NSCLCMasahiro Torasawa, Medical Oncologist at Juntendo University, shared on X: “FDA declines to approve ivonescimab (PD-1 × VEGF) + chemotherapy for EGFR-mutated NSCLC after EGFR-TKI therapy. Despite significant PFS improvement
-
F.D.A. Rejects Closely Watched Lung Cancer Drug From ChinaThis X-ray shows stage 1 cancer. Summit Therapeutics of Florida had been seeking to bring to the U.S. market a drug for lung cancer, called ivonescimab, that was invented in China.
-
FDA rejects ivonescimab application for NSCLC typesThe FDA issued a complete response letter to Summit Therapeutics stating it cannot approve the company’s biologic license application for ivonescimab as treatment for EGFR-mutated, locally advanced or metastatic non-small cell lung cancer. The company had submitted the application for ivonescimab…
-
FDA Declines Ivonescimab Plus Chemotherapy Approval in EGFR-Mutated NSCLC Following HARMONi ResultsSummit Therapeutics announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter for its biologics license application for ivonescimab plus platinum-containing chemotherapy in previously treated, locally
-
Nicholas Hornstein: FDA Rejects Ivonescimab Despite PFS Benefit in EGFR-Mutant NSCLCNicholas Hornstein, Gastrointestinal Medical Oncologist at Northwell Health Cancer Institute and Assistant Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared on X: “Interesting weekend surprise.
-
Aakash Desai: What Does the FDA Decision Mean for Ivonescimab in EGFR-Mutant NSCLC?Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on LinkedIn: “The FDA issued a complete response letter for ivonescimab (PD-1 × VEGF bispecific) + platinum chemotherapy in EGFR-mutant
-
FDA Withholds Ivonescimab Approval in EGFR-Mutant NSCLC: Why HARMONi’s PFS Benefit Was Not EnoughThe US Food and Drug Administration has issued a Complete Response Letter for ivonescimab plus platinum-based chemotherapy in EGFR-mutated advanced non-small-cell lung cancer following EGFR tyrosine kinase inhibitor treatment. Announced
-
Estela Rodriguez: FDA Declines to Approve Summit Therapeutics Ivonescimab For Lung CancerEstela Rodriguez, Associate Director of Community Outreach in Thoracic Oncology at the University of Miami’s Sylvester Comprehensive Cancer Center, shared on X: “It’s been a weird week. Planes grounded, Outlook
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.